CEACAM6: A Potential Drug Target and Biomarker (G4680)

Target Name: CEACAM6

NCBI ID: G4680

CEACAM6

CEACAM6: A Potential Drug Target and Biomarker

The protein encoded by the gene CEACAM6 is a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. CEACAM6 is a member of the Camel gene family, which is known for the production of structurally similar proteins that play important roles in various cellular processes, including cell adhesion, migration, and signaling.

The CEACAM6 gene was first identified in 2001 and has since been shown to encode a protein that is expressed in a variety of tissues and cells, including brain, heart, liver, and muscle. The protein has a molecular weight of approximately 42 kDa and is composed of 251 amino acid residues.

CEACAM6 is involved in several cellular processes that are important for normal development and function. For example, it is involved in the regulation of cell adhesion and migration, as well as in the production of signaling molecules that are important for cell signaling. Additionally, CEACAM6 has been shown to play a role in the regulation of cellular stress responses, which are important for maintaining cellular homeostasis in the face of environmental stressors.

As a potential drug target, CEACAM6 is of particular interest because of its involvement in several diseases that are currently difficult to treat. For example, neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of progressive neurofibrillary changes. These disorders are typically treated with a combination of supportive care, medications to manage symptoms, and neuroprotective agents. However, there is a need for more effective treatments to slow the progression of these disorders and to improve the quality of life for patients.

In addition to its potential as a drug target, CEACAM6 is also a potential biomarker for several types of cancer. For example, studies have shown that CEACAM6 is overexpressed in a variety of cancer tissues and that it is involved in the development and progression of several types of cancer, including breast, lung, and colorectal cancers. Additionally, CEACAM6 has been shown to be associated with the development of cancer-associated autoimmune diseases, such as rheumatoid arthritis and lupus.

The potential utility of CEACAM6 as a drug target and biomarker makes it an attractive target for further study. Researchers are currently working to identify small molecules that can interact with CEACAM6 and to determine the molecular mechanisms that underlie its involvement in cellular processes. The results of these studies may provide insights into the potential therapeutic benefits of CEACAM6 and its potential as a drug or biomarker.

In conclusion, CEACAM6 is a protein that is involved in several cellular processes that are important for normal development and function. Its potential as a drug target and biomarker makes it an attractive target for further study, and the results of these studies may provide insights into the potential therapeutic benefits of CEACAM6. Further research is needed to fully understand the role of CEACAM6 in cellular processes and to determine its potential as a drug or biomarker.

Protein Name: CEA Cell Adhesion Molecule 6

Functions: Cell surface glycoprotein that plays a role in cell adhesion and tumor progression (PubMed:2803308, PubMed:2022629, PubMed:1378450, PubMed:8776764, PubMed:11590190, PubMed:10910050, PubMed:14724575, PubMed:16204051). Intercellular adhesion occurs in a calcium- and fibronectin-independent manner (PubMed:2022629, PubMed:16204051). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8 (PubMed:2803308, PubMed:2022629, PubMed:8776764, PubMed:11590190, PubMed:16204051). Heterophilic interaction with CEACAM8 occurs in activated neutrophils (PubMed:8776764). Plays a role in neutrophil adhesion to cytokine-activated endothelial cells (PubMed:1378450). Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion (PubMed:16204051). Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells (PubMed:10910050, PubMed:14724575)

The "CEACAM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets